Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-01

Study Completion Date

2022-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atherosclerosis is a progressive inflammatory disease of the large and medium sized arteries, which is characterized by the formation of plaques in the vessel wall. The morphology and composition of the plaque play a major role in its stability during the development of the disease.

The CTS system allows to deliver coronary cryotherapy intended for stabilization of vulnerable plaque with non-significant stenosis. Vulnerable plaque at high risk of rupture will be assessed by NIRS-IVUS imaging modality in patients with Acute Coronary Syndrome (ACS).

The ICEBERG study is an early feasibility single arm study enrolling a maximum of 45 patients. After enrolment of the first 5 patients in the First-in-Man safety cohort, the trial will enroll and randomize 40 eligible lesions in the randomized cohort of which 20 will be treated with cryotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study

NCT06939374

Coronary Arterial Disease (CAD) Plaque Vulnerable Plaque +4 more

NOT_YET_RECRUITING NA

Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable Angina

NCT05600088

Coronary Artery Disease Coronary Syndrome Cryotherapy Effect +3 more

RECRUITING NA

"SIMULATION MODELING OF CORONARY ARTERY DISEASE: A TOOL FOR CLINICAL DECISION SUPPORT"

NCT04448691

Management/Treatment of Coronary Artery Disease

COMPLETED NA

Advanced Ultrasound Methods in the Assessment of Carotid Plaque Instability

NCT03672955

Internal Carotid Artery Stenosis With Infarction

ACTIVE_NOT_RECRUITING

Vascular Changes in Patients With Aotic Isthmus Stenosis After Interventional Therapy

NCT05903586

Aortic Isthmus Stenosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTS device

Group Type EXPERIMENTAL

CTS Device

Intervention Type DEVICE

Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.

Control

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTS Device

Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women at least 18 years old.
* Acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:

1. Non ST-segment elevation myocardial infarction (NSTEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring Percutaneous Coronary Intervention (PCI) within 72 hours from diagnosis
2. Stabilized ST-segment elevation myocardial infarction (STEMI) with at least one value above the 99th percentile of the upper reference limit requiring PCI within \< 12 hours from symptoms onset.
3. Unstable angina with new or worsening angina symptoms over the last 2 weeks requiring PCI within 72 hours.
* Patient must have one, two or three-vessel disease in native coronary arteries.
* PCI of the culprit lesion on all patients.
* At least one lesion meeting the criteria below:

1. Located in a non-culprit vessel, or proximal to the culprit lesion if located in the culprit vessel with at least 10 mm distance from the culprit lesion.
2. Lesion stenosis ≤ 70% of the reference vessel diameter by visual assessment on coronary angiogram.
3. Plaque-level maxLCBI4mm ≥ 325 by NIRS (Near-Infrared Spectroscopy).
4. Plaque burden ≥ 65% by IVUS (IntraVascular UltraSound).
5. Not intended for revascularization based on angiographic criteria and negative physiology assessment (FFR\>0.80 or iFR/RFR\>0.89).
6. Lesion-level balloon to artery ratio \> 1.0.
7. Lesion length ≤ 20 mm.
8. Investigator considers that lesions are accessible.
9. If more than two suitable lesions available, investigator will select two lesions for randomization.
* Subject able to consent and has a signed and dated the informed consent form.

Exclusion Criteria

* Unstable patients (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).
* Patients with ongoing ST-segment elevation myocardial infarction.
* Patients that had a procedural complication during the PCI procedure, such as coronary dissection, perforation or a complication that would necessitate immediate and/or unplanned surgical revascularization.
* History of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.
* Known ejection fraction \< 30%.
* Known severe valvular heart disease.
* Known severe renal insufficiency (eGFR \<30 ml/min/1.72 m2).
* Any life-threatening conditions or medical comorbidity resulting in life expectancy \< 12 months.
* Participation in any investigational study that has not yet reached its primary endpoint.
* Women who are pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or women with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).

* Visible distal embolization/no-reflow following culprit PCI.
* Left main coronary artery disease (visual diameter stenosis \> 50%).
* Stent thrombosis/restenosis as a culprit lesion.
* Index lesion involving a bifurcation.
* Angiographic evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No